ISOFLURANE USP LIQUID
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
23-05-2018
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
ISOFLURANE
Tilgængelig fra:
FRESENIUS KABI CANADA LTD
ATC-kode:
N01AB06
INN (International Name):
ISOFLURANE
Dosering:
99.9%
Lægemiddelform:
LIQUID
Sammensætning:
ISOFLURANE 99.9%
Indgivelsesvej:
INHALATION
Enheder i pakken:
100/250ML
Recept type:
Prescription
Terapeutisk område:
INHALATION ANESTHETICS
Produkt oversigt:
Active ingredient group (AIG) number: 0114368001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2006-10-05
Produktets egenskaber
PRODUCT
MONOGRAPH
PR
ISOFLURANE USP
(Isoflurane, 99.9%)
Inhalation Anesthetic
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Revision:
May 23, 2018
Control No.: 215732
Isoflurane USP - Product Monograph_ _
Page 2 of 26
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT
INFORMATION.................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
............................................................................................................
8
DRUG INTERACTIONS
..........................................................................................................
11
DOSAGE AND ADMINISTRATION
......................................................................................
13
OVERDOSAGE
.........................................................................................................................
15
STORAGE AND STABILITY
..................................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 17
PART II: SCIENTIFIC INFORMATION
...............................................................................18
PHARMACEUTICAL INFORMATION
..................................................................................
18
DETAILED PHARMACOLOGY
.............................................................................................
19
TOXICOLOGY
.................................................................................................................
Læs hele dokumentet
